Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors

NCT04674683 is registered in ClinicalTrials.gov with HUYABIO International, LLC. as lead sponsor.

NCT NCT04674683
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04674683 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-Blind Phase 3 Study of HBI-8000 Combined With Nivolumab Versus Placebo With Nivolumab in Patients With Unresectable or Metastatic Melanoma Not Previously Treated With PD-1 or PD-L1 Inhibitors
Lead sponsor
HUYABIO International, LLC.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
August 12, 2021
Completion date
December 31, 2026
Enrollment
450 (actual)
Sites
139

Conditions

As the registry lists them; a condition with its own page is linked.

progressive brain metastasis, unresectable or metastatic melanoma